Translational Neuroscience, published by DE GRUYTER POLAND SP Z O O, is a leading open-access journal since its inception in 2015, dedicated to the multidisciplinary exploration of neurological research and its clinical applications. With an ISSN of 2081-3856 and an E-ISSN of 2081-6936, the journal serves as a crucial platform for scholars and practitioners to disseminate innovative findings and theoretical advancements in the field of neuroscience. Covering various aspects of general neuroscience, it is ranked in the Q3 quartile for 2023 and positioned at Rank #75 out of 113 in its category, reflecting its growing impact within the scientific community. The journal strives to bridge the gap between laboratory research and clinical practice, fostering collaboration among researchers, clinicians, and educators. The editorial team is committed to maintaining high publication standards that engage the audience with rigorous research while promoting a culture of open science. For those interested in the forefront of neuroscience research, Translational Neuroscience offers an invaluable resource for knowledge and innovation.

ACTA PHARMACOLOGICA SINICA is a premier journal in the field of pharmacology, published by the esteemed Nature Publishing Group. With a strong history since its inception in 1980, this journal is recognized for its impactful contributions to the fields of medicine and pharmacology, consistently securing a Q1 ranking in multiple relevant categories, including Pharmacology (Medical). Drawing on a robust international readership, it ranks impressively at #8 out of 272 in the specialty of Medical Pharmacology, placing it in the top 97th percentile according to Scopus data. Although currently not an open-access publication, ACTA PHARMACOLOGICA SINICA remains a vital resource for researchers, professionals, and students seeking to advance their understanding of pharmacological sciences. Its commitment to disseminating high-quality research underscores its significance in fostering innovation and exploration in the medical landscape.

MEDICINAL RESEARCH REVIEWS, published by Wiley, is a leading journal in the fields of Drug Discovery, Molecular Medicine, and Pharmacology. With an impressive impact factor and esteemed standing in its category quartiles (Q1 in all three fields), this journal serves as a vital platform for the dissemination of cutting-edge research and reviews that drive innovation in therapeutic development and molecular health sciences. Since its inception in 1981, MEDICINAL RESEARCH REVIEWS has garnered a robust readership within the scientific community, underscored by its high rankings in Scopus – where it ranks #3 in Pharmacology and #2 in Drug Discovery, placing it within the top echelons of academic influence. Researchers, professionals, and students alike benefit from its rich content and comprehensive approaches to tackling complex medicinal challenges, making it an essential resource for those invested in advancing the frontiers of biomedical research.

NEUROMOLECULAR MEDICINE, published by HUMANA PRESS INC, is a prestigious peer-reviewed journal dedicated to advancing the fields of cellular and molecular neuroscience, molecular medicine, and neurology. With an ISSN of 1535-1084 and an E-ISSN of 1559-1174, the journal boasts a significant presence in academic research since its inception in 2002 and continues to publish cutting-edge studies through 2024. Ranked in the Q2 category for 2023 in various disciplines, including Neuroscience and Molecular Medicine, it holds impressive positions in Scopus rankings, including 41st out of 192 in Neuroscience and Neurology. Although not an open access journal, NEUROMOLECULAR MEDICINE remains invaluable for researchers, professionals, and students seeking to explore the intricate relationships between molecular mechanisms and neurological functions, thereby contributing to the scientific understanding of nervous system diseases and therapeutic innovations.

Current Molecular Pharmacology, published by Bentham Science Publishers, is a prominent journal focused on the dynamic fields of pharmacology, drug discovery, and molecular medicine. With an ISSN of 1874-4672 and an E-ISSN of 1874-4702, this journal aims to disseminate cutting-edge research and review articles that showcase innovative methodologies and groundbreaking findings from 2008 through 2024. Holding a respectable Q3 category ranking in Drug Discovery, Molecular Medicine, and Pharmacology for 2023, Current Molecular Pharmacology serves as an essential platform for both established researchers and emerging scholars to share their insights. The journal is indexed in Scopus with its relevant ranks catering to pharmacology and molecular biology, ensuring it reaches a wide array of professionals, researchers, and students in the field. As a contributor to advancing pharmacological sciences, this journal provides invaluable access to the latest advancements and fosters ongoing dialogue in molecular pharmacology, positioning itself as a key resource in the exploration of therapeutic agents and their interactions.

Welcome to the International Journal of Immunopathology and Pharmacology, a premier publication dedicated to advancing the fields of immunology and pharmacology. Published by SAGE Publications Inc., this Open Access journal has been a vital resource since its inception in 1989, providing an expansive platform for innovative research and comprehensive reviews until 2024. With a strong focus on the mechanisms of immune responses and therapeutic developments, our journal stands out with a 2023 impact factor reflected in its Q3 ranking in Immunology and Allergy, and a Q2 ranking in Pharmacology. The journal's Scopus rankings highlight its significance, ranking #174 in Pharmacology, #141 in Medicine, and #156 in Immunology, all affirming its role in contributing to the broader scientific community. Through rigorous peer review and a commitment to high-quality research, the International Journal of Immunopathology and Pharmacology continues to be an essential resource for scientists, healthcare professionals, and students striving to enhance their knowledge and understanding in these critical fields.

CNS & Neurological Disorders-Drug Targets is a distinguished journal that focuses on contemporary research and advancements in the realms of neurology, pharmacology, and drug development. Published by Bentham Science Publishers, this journal serves as an essential platform for researchers, professionals, and students interested in the intricate workings of the central nervous system and the evolving strategies to target neurological disorders through pharmacological innovations. With a robust impact factor reflecting its academic relevance, CNS & Neurological Disorders-Drug Targets is categorized in the Q2 quartile for both Medicine (miscellaneous) and Pharmacology, and Q3 for Neuroscience in the 2023 rankings. The journal's Scopus rankings further reinforce its authority, positioning it within the top half of its categories. Operating out of the United Arab Emirates, the journal has been a loyal contributor to the scientific discourse since its inception in 2006 and will continue until at least 2024, ensuring a dynamic channel for the latest findings and reviews in this vital field. As an open-access publication, it prioritizes accessibility, thus fostering a wider impact among scholars and practitioners alike, making it a valuable resource for all stakeholders in neurological and pharmacological research.

BRAIN RESEARCH BULLETIN is a leading academic journal published by PERGAMON-ELSEVIER SCIENCE LTD, dedicated to the dissemination of high-quality research in the interdisciplinary field of neuroscience. Since its inception in 1976, this journal has served as a vital platform for researchers, professionals, and students interested in a broad spectrum of topics within neuroscience, making significant contributions to the understanding of brain function and its associated disorders. With a commendable impact factor and a current Scopus rank of #35 out of 113 in general neuroscience, the journal holds a Q2 quartile ranking, underscoring its relevance and influence in the academic community. BRAIN RESEARCH BULLETIN invites submissions of original articles, reviews, and brief communications, enhancing scholarly communication within this dynamic field. Although the journal is not open access, it ensures widespread reach and impact through various subscription models, allowing access to pivotal findings that pave the way for future research advancements. For researchers aiming to share impactful discoveries and insights within the neuroscience community, BRAIN RESEARCH BULLETIN remains an essential outlet.

NEUROSCIENTIST is a leading journal in the field of clinical neurology and neuroscience, published by SAGE Publications Inc. With an impressive impact factor reflected in its Q1 quartile ranking in both clinical neurology and miscellaneous neuroscience as of 2023, this journal positions itself as a crucial platform for the latest research and advancements in the neural sciences. Spanning from 1995 to 2024, NEUROSCIENTIST features a range of high-quality, peer-reviewed articles that cater to researchers, practitioners, and students alike. Although it does not offer Open Access options, the journal remains a vital resource owing to its Scopus rankings, situating it within the top percentile of its categories: ranked #28 out of 400 in clinical neurology and #15 out of 113 in general neuroscience. The journal's commitment to disseminating significant findings underlines its importance in fostering advancements in neurological understanding and treatment.

MOLECULAR PHARMACOLOGY, published by the American Society for Pharmacology and Experimental Therapeutics, is an influential peer-reviewed journal dedicated to advancing the field of pharmacology through comprehensive research on molecular mechanisms of drug action. With an impressive historic convergence from 1965 to 2024, this journal plays a pivotal role in disseminating high-quality research, showcasing significant findings that impact both clinical and experimental pharmacology. Notably, it holds a distinguished Q1 ranking in Pharmacology and a Q2 ranking in Molecular Medicine as of 2023, reflecting its prominence in the academic community. Researchers and practitioners engaged in pharmacological studies will benefit from the journal’s focus on new therapeutic strategies, drug development, and the molecular basis of drug action. While MOLECULAR PHARMACOLOGY is not an open-access journal, it offers a wealth of knowledge behind a subscription model, ensuring that contributors and readers maintain a high standard of academic rigor. Address all inquiries to the editorial office located at 9650 Rockville Pike, Bethesda, MD 20814-3995, United States.